IRD
Price
$4.31Alerts
Change
+$0.08 (+1.89%)
Updated
Nov 11 closing price
Capitalization
347.76M
Earnings call today
Intraday BUY SELL Signals
SRPT
Price
$16.68Alerts
Change
+$0.26 (+1.58%)
Updated
Nov 11 closing price
Capitalization
1.88B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IRD vs SRPT

IRD vs SRPT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IRD vs. SRPT commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRD is a Hold and SRPT is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IRD with price predictions
Nov 10, 2026

IRD in +1.20% Uptrend, rising for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IRD advanced for three days, in 215 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IRD's RSI Indicator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IRD as a result. In 89 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for IRD just turned positive on November 03, 2026. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.

IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

IRD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IRD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for IRD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.779) is normal, around the industry mean (3.498). P/E Ratio (-3.240) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SRPT with price predictions
Nov 10, 2026

SRPT in upward trend: price may jump up because it broke its lower Bollinger Band on November 10, 2026

SRPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 40 cases where SRPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 50-day moving average for SRPT moved above the 200-day moving average on October 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in 223 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRPT as a result. In 66 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for SRPT turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

SRPT moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for SRPT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.232) is normal, around the industry mean (3.498). P/E Ratio (-12.205) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.125) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. SRPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
IRD vs SRPT: Fundamental Ratings
IRD
SRPT
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
4569
P/E GROWTH RATING
1..100
8498
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRD's Valuation (5) in the null industry is in the same range as SRPT (12) in the Biotechnology industry. This means that IRD’s stock grew similarly to SRPT’s over the last 12 months.

IRD's Profit vs Risk Rating (100) in the null industry is in the same range as SRPT (100) in the Biotechnology industry. This means that IRD’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (93) in the Biotechnology industry is in the same range as IRD (100) in the null industry. This means that SRPT’s stock grew similarly to IRD’s over the last 12 months.

IRD's Price Growth Rating (45) in the null industry is in the same range as SRPT (69) in the Biotechnology industry. This means that IRD’s stock grew similarly to SRPT’s over the last 12 months.

IRD's P/E Growth Rating (84) in the null industry is in the same range as SRPT (98) in the Biotechnology industry. This means that IRD’s stock grew similarly to SRPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IRDSRPT
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 17 days ago
82%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (IRD: $4.23 vs. SRPT: $16.42)
Brand notoriety: IRD: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IRD: 33% vs. SRPT: 131%
Market capitalization -- IRD: $347.76M vs. SRPT: $1.88B
IRD [@Biotechnology] is valued at $347.76M. SRPT’s [@Biotechnology] market capitalization is $1.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IRD’s FA Score shows that 1 FA rating(s) are green while SRPT’s FA Score has 1 green FA rating(s).

  • IRD’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 1 green, 4 red.
According to our system of comparison, IRD is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IRD’s TA Score shows that 5 TA indicator(s) are bullish while SRPT’s TA Score has 4 bullish TA indicator(s).

  • IRD’s TA Score: 5 bullish, 5 bearish.
  • SRPT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, IRD is a better buy in the short-term than SRPT.

Price Growth

IRD (@Biotechnology) experienced а +7.63% price change this week, while SRPT (@Biotechnology) price change was -11.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

IRD is expected to report earnings on Nov 11, 2026.

SRPT is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IRD and

Correlation & Price change

A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRD
1D Price
Change %
IRD100%
+0.71%
ARRY - IRD
35%
Loosely correlated
-8.86%
PRME - IRD
34%
Loosely correlated
-9.30%
DMAC - IRD
34%
Loosely correlated
+0.21%
FDMT - IRD
33%
Poorly correlated
-0.16%
SRPT - IRD
32%
Poorly correlated
-4.76%
More

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with RCKT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
-4.76%
RCKT - SRPT
51%
Loosely correlated
-3.16%
DNLI - SRPT
49%
Loosely correlated
-2.36%
DYN - SRPT
48%
Loosely correlated
-3.76%
SANA - SRPT
48%
Loosely correlated
-1.42%
PRLD - SRPT
47%
Loosely correlated
N/A
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AGCC14.470.42
+2.99%
Agencia Comercial Spirits Ltd
AFJK12.310.27
+2.24%
Aimei Health Technology Co Ltd
MOS22.990.22
+0.97%
Mosaic Company (The)
GE337.912.37
+0.71%
GE Aerospace
LKFN62.09-0.11
-0.18%
Lakeland Financial Corp